Issuing a new set of guidelines for the use of drugs against swine flu, the World Health Organization has said otherwise patients with uncomplicated illnesses do not need to take antiviral drugs.
Worldwide, most infected patients continue to display typical influenza symptoms and fully recover within a week without any form of medical treatment, the WHO said.
According to the new guidelines, formed by consensus by a global group of experts, patients with uncomplicated illnesses do not need to be treated with antiviral medicines.
The guidelines emphasise using drugs such as oseltamivir and zanamivir, to which the pandemic virus is susceptible, to prevent severe illness and deaths, reduce the need for hospitalisation, and shorten hospital stays.
When properly prescribed, oseltamivir is found to significantly curb the risk of pneumonia, a leading cause of death for both the pandemic and seasonal influenza, it said.
WHO recommends treatment with the drug as soon as possible among people who are severely or whose conditions begin to deteriorate. Where oseltamivir is not available, zanamivir can be given. The virus is currently resistant to a second class of antiviral, known as M2 inhibitors.
As pregnant women are among the groups considered to be at increased risk, WHO recommends that they receive antiviral treatment as soon as possible after the onset of symptoms.
The guidelines call for prompt treatment for children ¿ including those under five years of age ¿ with severe or worsening illnesses, as well as those at risk of more severe or complicated illness.
Otherwise healthy children over five years, WHO said, do not need antiviral treatment unless their conditions persist or worsen.
If someone with confirmed or suspected H1N1 infections shows symptoms including shortness of breath, chest pain and high fever lasting beyond three days, they should seek immediate medical attention.
Among children, warning signs include fast or difficult breathing, lack of alertness, difficulty in waking up and little or no desire to play.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
